Table 3.
A1C at 26 weeks by treatment group
| Treatment group |
P | ||
|---|---|---|---|
| CGM | Control | ||
| n | 67 | 62 | |
| A1C* | |||
| Baseline (%) | 6.4 ± 0.5 | 6.5 ± 0.3 | |
| 26 weeks (%) | 6.4 ± 0.5 | 6.8 ± 0.5 | |
| Change from baseline to 26 weeks (%) | +0.02 ± 0.45 | +0.33 ± 0.43 | |
| Treatment group difference (%)† | −0.34 (−0.49 to −0.20) | <0.001 | |
| Decrease by ≥0.3% from baseline to 26 weeks | 21 (31) | 3 (5) | <0.001 |
| Increase by ≥0.3% from baseline to 26 weeks | 19 (28) | 31 (52) | 0.002 |
| Subjects who maintained A1C <7.0 at 26 weeks | 59 (88) | 38 (63) | <0.001 |
Data are means ± SD, difference (95% CI), or n (%).
*26-week A1C data were not available for 2 subjects in the control group.
†ANCOVA model adjusted for baseline A1C and site. The negative value denotes lower A1C in the CGM group compared with that in the control group.